Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study

Plain-language guide to PMID 42684246 (2026): observational study of Semaglutide, fat loss, obesity & body recomposition.

Key Facts

PMID: 42684246
Journal: Journal of medical Internet research
Year: 2026
Study type: Observational Study
Authors: Tournayre S et al. (13 authors)
DOI: 10.2196/80119

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Semaglutide in the context of fat loss, obesity & body recomposition, published as an observational study.

Digital platforms may support engagement, but their role remains poorly characterized.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Baseline engagement with the Aviitam digital assessment platform was operationalized as a 3-level ordinal variable (never used, partial use, and full completion of validated questionnaires), reflecting the patient's responses to a nonenforced preclinical request.

Adjusted logistic and linear regressions estimated the engagement-persistence and engagement-weight-loss associations.

How the Study Was Run

A Baron-Kenny mediation analysis with bootstrap CIs decomposed the engagement-weight-loss association.

Missing 48-week weights were imputed using multiple imputation (m=20) as a sensitivity analysis.

Among persistent participants who completed all 7 baseline questionnaires (n=91), behavioral-scale associations with weight change were analyzed using Benjamini-Hochberg false-discovery-rate correction.

What Was Measured

PubMed files the paper under topics including Semaglutide, Weight Loss, Glucagon-Like Peptides, Obesity, Morbid and Anti-Obesity Agents.

The authors tagged it with the keywords GLP-1 receptor agonist, behavioral predictors, digital engagement, real-world study, severe obesity and treatment adherence.

What This Means in Plain Language

This is an observational study of Semaglutide in people with fat loss, obesity & body recomposition.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Journal of medical Internet research), a journal based in Canada.

More context: the Semaglutide compound page, Fat loss, obesity & body recomposition research.

Our Notes on the Compound

Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.